Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Resalis Therapeutics Appoints Diana M. Røpcke As Chief Medical Officer

PRIVATESep 02, 2026•6 days ago

Position

Chief Medical Officer

Company

Resalis Therapeutics

Diana M. Røpcke
TurinBiotechnology

Description

Resalis Therapeutics has announced the appointment of Dr. Diana M. Røpcke as Chief Medical Officer

Company Information

Company

Resalis Therapeutics

Location

Turin, Piedmont, Italy

About

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Don't miss Resalis Therapeutics's next move

Get an email the moment Resalis Therapeutics changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
Alessandro
Likely contact at this company
••••••••@••••••••

See Alessandro's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Resalis Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Resalis Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.